Early neoadjuvant chemotherapy response predicts survival in cervical cancer
An early response to neoadjuvant chemotherapy (NACT) in cervical cancer patients is significantly associated with higher disease-free survival (DFS) and improved survival rates, a recent study has shown.
Researchers performed a meta-analysis of six studies involving 490 cervical cancer patients, of whom 336 were responders and 154 were nonresponders. Included studies were those that evaluated the survival of early NACT responders, and were retrieved from PubMed and Embase databases.
Pooled data from the six studies showed that nonreponders had significantly lower 1-year overall survival compared with cervical cancer patients with early response to NACT (hazard ratio [HR], 0.25; 95 percent CI, 0.10–0.58), with nonsignificant heterogeneity (p=0.882).
The trend was similar with 2-year overall survival, where early responders showed significantly better survival than nonresponders (HR, 0.28; 0.15–0.56).
The forest plot for combined DFS in the third year likewise showed that results were significantly worse for those without early response to NACT relative to early responders (HR, 0.27; 0.16–0.45). Heterogeneity was again nonsignificant (p=0.511).
The results were similar for 4-year (HR, 0.29; 0.17–0.50) and 5-year (HR, 0.33; 0.20–0.54) survival rates.
“By combining previous study results, the present study found that a short-term response was significantly associated with the long-term survival of cervical cancer patients who underwent NACT,” said researchers.
“This finding may help doctors to evaluate the survival of this group of patients and may help to determine more effective treatment methods. Future [randomized clinical trials] should be performed to validate our results and to provide clear conclusions with less bias,” they added.